DECLARE-TIMI 58 (post-hoc analysis)
Trial question
What is the effect of dapagliflozin on hospitalizations in adults with T2DM?
Study design
Multi-center
Double blinded
RCT
Population
Characteristics of study participants
37.0% female
63.0% male
N = 17160
17160 patients (6422 female, 10738 male).
Inclusion criteria: adult patients aged ≥ 40 years with T2DM and either risk factors for or established ASCVD.
Key exclusion criteria: diagnosis of T1DM mellitus; chronic cystitis; recurrent UTIs; pregnancy.
Interventions
N=8582 dapagliflozin (at an oral dose of 10 mg once daily).
N=8578 placebo (matching placebo once daily).
Primary outcome
First non-elective hospitalization for any cause
32.4%
35.4%
35.4 %
26.5 %
17.7 %
8.8 %
0.0 %
Dapagliflozin
Placebo
Significant
decrease ▼
NNT = 33
Significant decrease in first non-elective hospitalization for any cause (32.4% vs. 35.4%; HR 0.89, 95% CI 0.85 to 0.94).
Conclusion
In adult patients aged ≥ 40 years with T2DM and either risk factors for or established ASCVD, dapagliflozin was superior to placebo with respect to first non-elective hospitalization for any cause.
Reference
Meir Schechter, Stephen D Wiviott, Itamar Raz et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023 Apr;11(4):233-241.
Open reference URL